Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BEAT advanced for three days, in 169 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day RSI Indicator for BEAT moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 21 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BEAT as a result. In 79 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for BEAT turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 36 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
BEAT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BEAT crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
BEAT broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BEAT entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.743) is normal, around the industry mean (3.981). P/E Ratio (-0.781) is within average values for comparable stocks, (13.628). Projected Growth (PEG Ratio) (0.290) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. BEAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The RSI Oscillator for PRPO moved into overbought territory on October 22, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRPO advanced for three days, in 195 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
PRPO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRPO as a result. In 78 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
PRPO moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PRPO crossed bearishly below the 50-day moving average on September 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRPO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for PRPO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.500) is normal, around the industry mean (66.046). P/E Ratio (-33.242) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.715) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. PRPO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRPO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
BEAT | PRPO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 97 | 75 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 58 Fair valued | 29 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 93 | |
PRICE GROWTH RATING 1..100 | 83 | 75 | |
P/E GROWTH RATING 1..100 | 16 | 27 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PRPO's Valuation (29) in the Biotechnology industry is in the same range as BEAT (58) in the Medical Specialties industry. This means that PRPO’s stock grew similarly to BEAT’s over the last 12 months.
PRPO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BEAT (100) in the Medical Specialties industry. This means that PRPO’s stock grew similarly to BEAT’s over the last 12 months.
PRPO's SMR Rating (93) in the Biotechnology industry is in the same range as BEAT (100) in the Medical Specialties industry. This means that PRPO’s stock grew similarly to BEAT’s over the last 12 months.
PRPO's Price Growth Rating (75) in the Biotechnology industry is in the same range as BEAT (83) in the Medical Specialties industry. This means that PRPO’s stock grew similarly to BEAT’s over the last 12 months.
BEAT's P/E Growth Rating (16) in the Medical Specialties industry is in the same range as PRPO (27) in the Biotechnology industry. This means that BEAT’s stock grew similarly to PRPO’s over the last 12 months.
| BEAT | PRPO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 77% | 1 day ago 89% |
| Momentum ODDS (%) | 1 day ago 90% | 2 days ago 84% |
| MACD ODDS (%) | 1 day ago 88% | N/A |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 83% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 85% |
| Advances ODDS (%) | 7 days ago 84% | 18 days ago 81% |
| Declines ODDS (%) | 1 day ago 88% | 1 day ago 85% |
| BollingerBands ODDS (%) | 1 day ago 83% | 1 day ago 84% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 84% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BEAT’s FA Score shows that 1 FA rating(s) are green while PRPO’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BEAT’s TA Score shows that 2 TA indicator(s) are bullish while PRPO’s TA Score has 4 bullish TA indicator(s).
BEAT (@Services to the Health Industry) experienced а +3.59% price change this week, while PRPO (@Medical Specialties) price change was -8.56% for the same time period.
The average weekly price growth across all stocks in the @Services to the Health Industry industry was -1.51%. For the same industry, the average monthly price growth was -3.63%, and the average quarterly price growth was +16.27%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.29%. For the same industry, the average monthly price growth was -6.63%, and the average quarterly price growth was +42.53%.
BEAT is expected to report earnings on Nov 12, 2026.
PRPO is expected to report earnings on Nov 13, 2026.
This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.
@Medical Specialties (-3.29% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
A.I.dvisor indicates that over the last year, BEAT has been loosely correlated with SNOW. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if BEAT jumps, then SNOW could also see price increases.
| Ticker / NAME | Correlation To BEAT | 1D Price Change % | ||
|---|---|---|---|---|
| BEAT | 100% | -2.19% | ||
| SNOW - BEAT | 37% Loosely correlated | -2.72% | ||
| APPN - BEAT | 33% Poorly correlated | +4.97% | ||
| MNDY - BEAT | 32% Poorly correlated | +6.70% | ||
| ZS - BEAT | 31% Poorly correlated | +2.78% | ||
| CRM - BEAT | 31% Poorly correlated | +3.52% | ||
More | ||||
A.I.dvisor tells us that PRPO and TNON have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PRPO and TNON's prices will move in lockstep.
| Ticker / NAME | Correlation To PRPO | 1D Price Change % | ||
|---|---|---|---|---|
| PRPO | 100% | -3.01% | ||
| TNON - PRPO | 27% Poorly correlated | -10.76% | ||
| INGN - PRPO | 25% Poorly correlated | +5.55% | ||
| XAIR - PRPO | 25% Poorly correlated | -4.70% | ||
| INBS - PRPO | 24% Poorly correlated | -2.60% | ||
| BEAT - PRPO | 24% Poorly correlated | -2.19% | ||
More | ||||